Biocon Biologicals' IPO only after integrating Viatris: CEO

The company's biosimilar arm is looking to complete the process by the end of March

- Ranjani Raghavan

Biocon Biologics Ltd, the biosimilar arm of Biocon, will consider a listing only after it completes the integration of its Viatris portfolio, which is due by the end of March, the company’s chief executive officer Sreehas Tambe said in an interview.

The company is also looking to secure US regulatory approval for Aspart (insulin biosimilar) and Bevacizumab (cancer biosimilar) before going ahead with its initial public offering, he added.

Biocon Biologics had acquired Viatris’ global biosimilar portfolio for $3.34 billion in November 2022 in a cash and equity transaction. Biocon had paid $2 billion in cash, including a $1.2 billion sustainability loan. It had also issued compulsorily convertible preference shares (CCPS) to Viatris worth around $1 billion.

Now, it is in the process of fully integrating this business with itself by taking control of Viatris’ operations. Currently, the Viatris management continues to runs parts of the business, according to the terms of agreement.